Avalo Therapeutics, a clinical stage biotechnology company with an office in Wayne, recently appointed of Jennifer Riley as its first chief strategy officer, effective Jan. 1.
The role will oversee corporate strategy and commercial and product pipeline planning to spur growth and innovation.
“We are thrilled to welcome Jennifer to Avalo in the newly established role of chief strategy officer,” Dr. Garry Neil, Avalo Therapeutics CEO and board chairman, said. “Jennifer brings extensive leadership experience, strategic acumen, and deep expertise in immunology, which will be invaluable as we advance our lead asset, AVTX-009, an anti-IL-1β monoclonal antibody currently in the LOTUS Phase 2 trial for hidradenitis suppurativa. This role is pivotal for Avalo as we refine our commercialization strategies and explore indication expansion.”
Riley has more than 20 years leadership experience in the biotechnology and pharmaceutical industries. She founded Northbrook Consulting where she advised more than 30 companies.
Avalo focuses on the treatment of immune dysregulation. AVTX-009 is a humanized monoclonal antibody that binds to interleukin-1β and neutralizes its activity.
The LOTUS Trial is a randomized, double-blind, placebo-controlled, parallel-group trial with two AVTX-009 dose regimens to evaluate the efficacy and safety in approximately 180 adults with moderate to severe hidradenitis suppurativa, a chronic inflammatory skin condition.